A5019154969- Gastric Cancer Management and Outcomes
- Gastrointestinal Tumor Research and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Bladder and Urothelial Cancer Treatments
- Metastasis and carcinoma case studies
- Neutropenia and Cancer Infections
- Genetic factors in colorectal cancer
- Urinary and Genital Oncology Studies
- Gastrointestinal disorders and treatments
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Esophageal Cancer Research and Treatment
- Economic and Financial Impacts of Cancer
- PI3K/AKT/mTOR signaling in cancer
- Venous Thromboembolism Diagnosis and Management
- Chronic Lymphocytic Leukemia Research
- RNA modifications and cancer
- Sarcoma Diagnosis and Treatment
- Soft tissue tumor case studies
- Lung Cancer Treatments and Mutations
- Case Reports on Hematomas
- Blood transfusion and management
Korea University
2021-2025
Korea University Medical Center
2021-2025
University of Ulsan
2015-2023
Asan Medical Center
2015-2023
Ulsan College
2015-2023
Atezolizumab-bevacizumab is the new standard of care for first-line treatment advanced hepatocellular carcinoma (HCC). However, optimal sequence therapy after disease progression on atezolizumab-bevacizumab unclear.This multinational, multicenter, and retrospective study assessed clinical outcomes patients with HCC who received subsequent systemic between July 2016 April 2019.Among 71 treated atezolizumab-bevacizumab, a total 49 were included in this analysis; median age was 60 years (range,...
We evaluated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with metastatic or unresectable colorectal cancer (mCRC) mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) POLE mutations.
Abstract Purpose The phase 3 ATTRACTION-2 study demonstrated that nivolumab monotherapy improved survival compared to placebo in patients with pretreated advanced gastric cancer (AGC). However, the efficacy of seems be limited a subset patients. Materials and methods predictive values blood neutrophil–lymphocyte ratio (NLR), serum Na, PD-L1 expression, MSI status, tumor EBV infection, mutation burden (TMB) were investigated AGC refractory ≥2 lines chemotherapy enrolled from Asan Medical...
This study aimed to explore the practices, perceptions, and barriers related specialty palliative care (SPC) referrals among oncologists in Korea, highlighting clinical implications of early integration. A cross-sectional online survey targeting board-certified hemato-oncology specialists was conducted between August 1-25, 2024. The assessed referral attitudes toward SPC integration, criteria, barriers, institutional characteristics. total 227 participated (response rate: 36.7%). Among them,...
Abstract Metastasis is the leading cause of mortality in colorectal cancer (CRC), with liver and lung being most common sites progression. Although early detection metastasis crucial for improving patient outcomes, non-invasive predictive strategies remain limited. Exosomes, a class extracellular vesicles encapsulating cell-derived proteins, DNA, mRNA, miRNA within lipid bilayer, closely reflect molecular characteristics their originating cells exhibit exceptional stability biological...
Background While some recent studies have reported the development of tuberculosis (TB) in patients exposed to immune checkpoint inhibitors (ICIs), there is limited evidence date. Therefore, we evaluated risk TB with cancer ICIs using National Health Insurance claims data South Korea. Methods Patients diagnostic codes for non-small cell lung cancer, urothelial carcinoma or melanoma between August 2017 and June 2019 were identified. The incidence rate standardized ratio (SIR) calculated both...
We evaluated the safety and efficacy of direct oral anticoagulants (DOACs) versus subcutaneous dalteparin for cancer-associated venous thromboembolism (CA-VTE) in patients with advanced upper gastrointestinal (GI) tract, hepatobiliary, or pancreatic cancer.This was a multicenter, randomized, open-label, phase II trial five centers. Patients randomly received rivaroxaban (15 mg twice daily 3 weeks, then 20 once daily)/apixaban (10 first 7 days, 5 daily) (200 IU/kg month, 150 daily)....
Abstract Background Paclitaxel is commonly used as a second-line therapy for advanced gastric cancer (AGC). The decision to proceed with chemotherapy and select an appropriate regimen critical vulnerable patients AGC progressing after first-line chemotherapy. However, no predictive biomarkers exist identify who would benefit from paclitaxel-based Methods This study included 288 receiving between 2017 2022 part of the K-MASTER project, nationwide government-funded precision medicine...
The clinical implications of tumor-infiltrating T cell subsets and their spatial distribution in biliary tract cancer (BTC) patients treated with gemcitabine plus cisplatin were investigated.A total 52 BTC palliative included. Multiplexed immunohistochemistry was performed on tumor tissues, immune infiltrates separately analyzed for the stroma, margin, core.The density CD8+ cells, FoxP3- CD4+ helper FoxP3+ regulatory cells significantly higher margin than stroma core. LAG3- or...
Abstract Purpose This study investigated the clinical utility of next‐generation sequencing (NGS) for detection genetic alterations and its implications on treatment lung adenocarcinoma in real‐world practice. Patients Methods Data were reviewed 391 patients with who underwent NGS between March 2017 October 2018. Formalin‐fixed, paraffin‐embedded archival samples used performing targeting 382 genes, including all exons 199 184 hotspots, partial introns 8 genes often rearranged cancer....
Purpose Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability‒high (MSI-H) colorectal cancer (CRC), and factors predicting treatment not been fully identified. This study aimed to identify potential biomarkers of PD-1/PD-L1 inhibitor MSI-H CRC. Materials Methods CRC enrolled in three blockade at Asan Medical Center (Seoul, Republic Korea) were screened...
The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the differences in AEs and their impact on use medical services during adjuvant This sub-study aimed compare incidence any grade ≥ 3 AEs, healthcare utilization, chemotherapy completion rate, dose intensity according sex.
Abstract The long‐term effects of tyrosine kinase inhibitors (TKIs), including imatinib, and surgical intervention on advanced gastrointestinal stromal tumor (GIST) were evaluated. All 379 patients had metastatic or recurrent GIST started 400 mg/d imatinib at the Asan Medical Center in periods 1 2 [2001‐2007 (33.2%) 2008‐2014 (66.8%), respectively]. Men constituted 60.4%; median patient age size initiation 58.6 (14.6‐85.5) years 51 (0‐324) mm, respectively, without differences between except...
Background/Aim: The aim of this study was to examine the efficacy and safety direct oral anticoagulants for cancer-associated venous thromboembolism (VTE) in patients with active cancer. Patients Methods: This included advanced unresectable/metastatic upper gastrointestinal (GI) or hepatopancreatobiliary (HPB) cancers high risks VTE bleeding. Results: No significant differences were noted potential bleeding factors between rivaroxaban (n=105) low-molecular-weight heparin (LMWH) (n=69)...
Abstract Background ZW49 is a novel, humanized, antibody-drug conjugate comprised of bispecific antibody directed against 2 non-overlapping HER2 epitopes and attached to proprietary auristatin toxin with protease-cleavable linker. Here we present data supporting the selection RD in an ongoing, first-in-human, dose escalation (DE) expansion (DX) study (NCT03821233).1 Methods The 3+3 DE phase evaluated safety tolerability IV (1-1.75 mg/kg QW; 1-2 Q2W; 2-3 Q3W) pts HER2+ cancers. DX further...
Abstract Background Immune checkpoint inhibitor (ICI) or irinotecan-based chemotherapy is frequently used after failure of second-line paclitaxel plus ramucirumab treatment for patients with locally advanced unresectable metastatic gastric cancer (AGC). This study aimed to compare the efficacy between ICI and as third-line in AGC. Methods We retrospectively reviewed AGC, whose started July 2019 June 2021 at 17 institutions Korea. The group included who received nivolumab pembrolizumab,...
Background This phase Ib study was performed to determine the safety of combination capecitabine with alpleisib (phosphatidylinositol 3-kinase catalytic subunit p110α blockade) and maximal tolerated dose (MTD) recommended ll (RP2D) this regimen in patients advanced solid tumors refractory standard therapy. The synergistic anti-tumor activity pharmacokinetics (PK) were investigated. Methods Dose escalation phases conducted cancers who therapy regardless PIK3CA mutation. Patients administered...
The purpose of this study was to evaluate the efficacy and safety induction chemotherapy with docetaxel, capecitabine, cisplatin (DXP) plus bevacizumab (BEV) on initially unresectable locally advanced gastric cancer (LAGC) or paraaortic lymph node (PAN) metastatic (GC).Patients LAGC PAN GC received six cycles (60 mg/m2 docetaxel intravenously day 1, 937.5 capecitabine orally twice daily days 1-14, 60 7.5 mg/kg BEV 1 every 3 weeks), followed by conversion surgery. primary endpoint R0...
This study aimed to identify novel biomarkers for metastatic colorectal cancer progression using exosomal RNA expression profiling. The profiles of 54 patients with mCRC were investigated. Exosomal profiling was performed at the time relapse immediately before metastasectomy and recurrence or after metastasectomy. up- down-regulated screened analyzed H-cluster, principle component analysis gene ontology. tissue profile liver metastases compared GSE 41258 set GSEA tools. We identified two...